Idiopathic Membranous Nephropathy
Conditions
Interventions
The experimental group :The experimental group received Tripterygium Glycosides Tablets in addition to the baseline treatment given to the control group. The dosage was 2 tablets (10 mg/tablet) orally
Control group:they were treated with rituximab injection (RTX). RTX administration (100 mg/vial): Dosage:1 g per dose,administered intravenously.Frequency:Two doses in total,with a 2-week interval bet
Sponsors
The Affiliated Hospital of Jining Medical Univercity
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Age = 18 years; 2) Diagnosis of IMN confirmed by renal biopsy, accompanied by typical nephrotic syndrome (NS) clinical manifestations; 3) Patients are informed about the study and provide signed informed consent.
Exclusion criteria
Exclusion criteria: 1) Secondary MN caused by autoimmune diseases (e.g.,systemic lupus erythematosus),drugs,viral hepatitis,malignancies,etc; 2) Patients with severe infections,psychiatric disorders,or neurological diseases; 3) Follow-up duration less than 12 months; 4) Patients allergic to the study medication; 5) Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24-hour urinary protein excretion; | — |
Secondary
| Measure | Time frame |
|---|---|
| peripheral blood CD19+ B cell levels;serum albumin;M-type phospholipase A2 receptor antibody(PLA2R antibody);serum creatinine; | — |
Countries
China
Contacts
Public ContactXiaofen Ma
The Affiliated Hospital of Jining Medical Univercity
Outcome results
None listed